Featured Articles
Trending Articles
AI in Life Sciences: Trends and Predictions for 2025 - By Doron Sitbon
AI | 21 February 2025
DNA-Based Immunotherapy IMNN-001 Promises to Improve Survival in Ovarian Cancer
Clinical Trials | 19 February 2025
New Data Confirms Darolutamide’s Safety and Efficacy in mHS Prostate Cancer
ONCOLife | 14 February 2025
How AI Innovations Are Transforming Breast Cancer Screening
ONCOLife | 30 January 2025
FDA Grants Priority Review to Datopotamab Deruxtecan for EGFR+ Lung Cancer
FDA & EMA | 14 January 2025
FDA Approves Innovative ADC Datroway for Metastatic HR+, HER2- Breast Cancer
FDA & EMA | 17 January 2025
Dr. Rafael Rosell Discusses the Efficacy of KRAS G12C Inhibitor in Lung Cancer Treatment
ONCOLife | 5 August 2024
FDA Approves Sotorasib and Panitumumab Combo for KRAS G12C+ Colorectal Cancer
FDA & EMA | 17 January 2025
FDA Approves 225Ac-SSO110 Radiopharmaceutical Trial for Small Cell Lung Cancer
FDA & EMA | 14 January 2025
How AI Could Overcome Data Scarcity to Transform Medicine
AI | 10 January 2025
The Internet of Medical Things needs a new security model to fulfil its potential
Digital Health | 13 January 2025
First-Ever Obstructive Sleep Apnea Drug, Zepbound, Approved by FDA for Obesity
FDA & EMA | 21 December 2024
How Qvin's Q-Pad Could Transform Women’s Health Through Menstrual Blood Testing
ONCOLife
16 December 2024
Palbociclib Combination Yields PFS Improvement in HR+, HER2+ Breast Cancer
Clinical Trials
14 December 2024
Olaparib Shows Long-term Survival Benefits in BRCA+ and HER2- Breast Cancer
Clinical Trials
13 December 2024
IL-15 Agonist NKTR-255 Enhances CAR-T Therapy Effectiveness in LB-Cell Lymphoma
Clinical Trials
11 December 2024
Elevation Partners with Synaffix in $368M Deal to Advance HER3 ADC Development
Pharma
12 December 2024
Blenrep Combination Reduces Death Risk by 42% in Relapsed Multiple Myeloma
Clinical Trials
10 December 2024
Breakthrough in First-Line Ovarian Cancer Treatment: KEYTRUDA and LYNPARZA
Clinical Trials
10 December 2024
FDA Grants Breakthrough Status to Datopotamab Deruxtecan for EGFR+ Lung Cancer
FDA & EMA
10 December 2024
Fixed-Duration Acalabrutinib Plus Venetoclax Achieves Superior 77% PFS in Untreated CLL
Clinical Trials
9 December 2024
Adding Blinatumomab to Chemotherapy Extends 96% DF Survival in Pediatric Leukemia
Clinical Trials
8 December 2024
AI-Driven Cancer Therapy: Recursion Doses First Patient in REC-1245 Trial for Solid Tumors
AI
6 December 2024